AIDS Treatment News logo      

July 29, 2009

Genotypic tests matches tropism test in predicting who benefits from CCR5 inhibitors

"A genotypic test is just as accurate as a more expensive tropism test in determining which treatment-experienced patients are suitable for treatment with the CCR5 inhibitor maraviroc, researchers from the University of British Columbia reported at the Fifth International AIDS Society conference in Cape Town last week.

"The finding opens the prospect of much cheaper testing to determine eligibility for CCR5 inhibitor treatment, and coincides with a re-analysis of 96-week results from the MERIT study showing that maraviroc is just as effective as efavirenz in treatment-naive patients, albeit better tolerated."

Read more in Aidsmap, July 29, 2009.